<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04693559</url>
  </required_header>
  <id_info>
    <org_study_id>AssiutU011270</org_study_id>
    <nct_id>NCT04693559</nct_id>
  </id_info>
  <brief_title>Assessment of Nanocrystalline Hydroxyapatite Versus Autogenous Bone Grafts : A Comparative Clinical Study in Alveolar Cleft Grafting</brief_title>
  <official_title>Assessment of Nanocrystalline Hydroxyapatite Versus Autogenous Bone Grafts : A Comparative Clinical Study in Alveolar Cleft Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This work aims to evaluate Nanocrystalline Hydroxyapatite versus Autogenous bone grafts in&#xD;
      alveolar cleft grafting&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alveolar cleft is the most common congenital bone defect. Since its introduction in 1972,&#xD;
      alveolar bone grafting (ABG) has been widely accepted to correct alveolar bone defect in most&#xD;
      cleft centres.The purpose of ABG is to restore the dental arch continuity, stabilize the&#xD;
      maxilla, close the oronasal fistulae, facilitate subsequent orthodontic treatment, enhance&#xD;
      nasal symmetry, establish better oral hygiene, limit growth disturbances, etc . Autologous&#xD;
      bone grafting is the gold standard for treating alveolar clefts, with the iliac crest , bone&#xD;
      being the most widely accepted donor site(Tan, Brogan et al. 1996.New bone graft substitutes&#xD;
      have been devised in recent decades, such as demineralized bone matrix (DBM), bone&#xD;
      morphogenetic proteins (BMPs), calcium phosphate (CP), calcium sulfate (CS), hydroxyapatite&#xD;
      (HA), highly purified bovine xenograft, and more, but clinical evidence of their efficacy&#xD;
      varies among clinical and experimental studies [4] With the advent of new biomaterials, which&#xD;
      may include or consist of allogenic bone source such as collagen membranes, hydroxyapatite&#xD;
      crystals, tricalcium phosphate powder that has been increased consideration for their&#xD;
      placement in the repair of alveolar clefts as well as other dental applications&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patient will be randomized into to groups according to the surgical procedures performed as follow</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring of bone volume 6 months post-operative</measure>
    <time_frame>6 months</time_frame>
    <description>compare between outcome of nanocrystalline hydroxyapatite versus autogenous bone graft in alveolar bone grafting regarding the newly formed bone volume</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alveolar Cleft</condition>
  <arm_group>
    <arm_group_label>autogenous iliac bone graft (group A)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>autogenous iliac bone graft will be used to fill the alveolar defect</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nano crystalline Hydroxyapatite (group B)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nano crystalline Hydroxyapatite will be used to fill the alveolar defect</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>secondary alveolar bone graft</intervention_name>
    <description>Under general anaesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will made on both the sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will dissected. Next, the bone particles will implanted into the bone defect. The cleft site will closed without tension by advancement of the gingival flaps</description>
    <arm_group_label>Nano crystalline Hydroxyapatite (group B)</arm_group_label>
    <arm_group_label>autogenous iliac bone graft (group A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>harvesting of the autogenous bone graft</intervention_name>
    <description>osteotome and then cut into small bone granules. The bone granules will then carefully placed into a syringe and pressed to its densest state by pushing the plunger</description>
    <arm_group_label>autogenous iliac bone graft (group A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nanocrystalline Hydroxyapatite</intervention_name>
    <description>Nanocrystalline Hydroxyapatite will be used to fill the alveolar defect</description>
    <arm_group_label>Nano crystalline Hydroxyapatite (group B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age (7 - 12 years )&#xD;
&#xD;
          -  Non-syndromic CLA or CLP&#xD;
&#xD;
          -  More than 6 months of follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of previous alveolar surgery&#xD;
&#xD;
          -  History of active infection or underlying disease such as hematologic disorders ,&#xD;
             neoplasm, and immune deficiency&#xD;
&#xD;
          -  Patients who had received primary or tertiary ABG&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abdullah Hashim, MBBS</last_name>
    <phone>+201148239460</phone>
    <email>abdulah011270@med.aun.edu.eg</email>
  </overall_contact>
  <reference>
    <citation>Boyne PJ, Sands NR. Secondary bone grafting of residual alveolar and palatal clefts. J Oral Surg. 1972 Feb;30(2):87-92.</citation>
    <PMID>4550446</PMID>
  </reference>
  <reference>
    <citation>Kyung H, Kang N. Management of Alveolar Cleft. Arch Craniofac Surg. 2015 Aug;16(2):49-52. doi: 10.7181/acfs.2015.16.2.49. Epub 2015 Aug 11. Review.</citation>
    <PMID>28913221</PMID>
  </reference>
  <reference>
    <citation>Cypher TJ, Grossman JP. Biological principles of bone graft healing. J Foot Ankle Surg. 1996 Sep-Oct;35(5):413-7.</citation>
    <PMID>8915864</PMID>
  </reference>
  <reference>
    <citation>Feinberg SE, Weisbrode SE, Heintschel G. Radiographic and histological analysis of tooth eruption through calcium phosphate ceramics in the cat. Arch Oral Biol. 1989;34(12):975-84.</citation>
    <PMID>2558643</PMID>
  </reference>
  <reference>
    <citation>Fernyhough JC, Schimandle JJ, Weigel MC, Edwards CC, Levine AM. Chronic donor site pain complicating bone graft harvesting from the posterior iliac crest for spinal fusion. Spine (Phila Pa 1976). 1992 Dec;17(12):1474-80.</citation>
    <PMID>1471005</PMID>
  </reference>
  <reference>
    <citation>Porter AE, Patel N, Skepper JN, Best SM, Bonfield W. Effect of sintered silicate-substituted hydroxyapatite on remodelling processes at the bone-implant interface. Biomaterials. 2004 Jul;25(16):3303-14.</citation>
    <PMID>14980425</PMID>
  </reference>
  <reference>
    <citation>Mankin HJ, Gebhardt MC, Jennings LC, Springfield DS, Tomford WW. Long-term results of allograft replacement in the management of bone tumors. Clin Orthop Relat Res. 1996 Mar;(324):86-97.</citation>
    <PMID>8595781</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 31, 2020</study_first_submitted>
  <study_first_submitted_qc>December 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Abdullah Hashim Ahmed</investigator_full_name>
    <investigator_title>MBBS</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

